Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%

NCT02527421 is registered in ClinicalTrials.gov with Primus Pharmaceuticals as lead sponsor.

NCT NCT02527421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02527421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%
Lead sponsor
Primus Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
August 19, 2015
Completion date
March 30, 2019
Enrollment
3 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis